Phase 4 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, of any sex
- People whose chronic kidney disease (CKD) has been present for a similar duration to other participants (matched for comparison purposes)
- People with CKD who are not on dialysis, and whose kidneys are functioning at a moderate level — specifically, a kidney filtration rate between 30 and 89 mL/min/1.73m² (known as Stage 2 to Stage 3b)
- People whose urine test shows a certain level of protein leakage from the kidneys (albumin-to-creatinine ratio of 30 mg/g or higher)
- People whose blood potassium level is below 5 mEq/L (within a normal-to-low range)
- People who have recently been diagnosed with high blood pressure
Who may not be able to join:
- People whose blood potassium level is 5 mEq/L or higher
- People who have diabetes
- People who have cancer
- People who have heart disease
- People who have liver or bile duct disease
- People who have kidney stones or a urinary tract infection
- People who have an overactive thyroid gland
- People who have a bleeding disorder
- People with a known allergy to a class of blood pressure medications called ACE inhibitors or ARBs
- Women who are pregnant or breastfeeding
- People whose blood pressure is very high (180/110 or above) or very low (below 100/60)
- People currently taking certain medications that could interact with the trial drug ramipril — including alteplase, azathioprine, everolimus, sirolimus, lithium, certain anti-inflammatory pain relievers (such as diclofenac, tenoxicam, or celecoxib), potassium-sparing water tablets (such as amiloride or spironolactone), or other ACE inhibitors or ARBs (confirm with trial site)
- People currently taking certain medications that could interact with vitamin K2 used in the trial — including omega-3 supplements, vitamins A, C, E, or K, chemotherapy drugs, the blood thinner warfarin, cholestyramine, or orlistat (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tarek Mostafa, PhD, Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt, 31527
Phone: +2001020198970
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The change in kidney function test measured by creatinine clearance (eGFR) mL/min/1.73m2 which will be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, 2021; The change in proteinuria level be assessed using Albumin-to-creatinine ratio (ACR) ratio (mg/g); The change in blood pressure (mmHg) will be done using a mercury sphygmomanometer; The change in Blood urea nitrogen (BUN) (mg/dl); The change in serum potassium (meq/l).; The change in serum creatinine (mg/dl); The change in serum urea (mg/dl)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.